抗血小板药物的临床研究进展

急性冠脉综合征（ACS）是一种常见的心血管疾病，可导致心律失常、心力衰竭、猝死等并发症，严重影响患者的生活质量和寿命。冠状动脉粥样硬化是ACS的发病基础，而血小板在动脉粥样硬化形成过程中起着关键作用。因此，抗血小板治疗是冠心病治疗的基石。目前临床常用的抗血小板药物主要有:血栓素A2抑制剂、P2Y12受体拮抗剂及糖蛋白Ⅱb/Ⅲa抑制剂，另外，有多种新型抗血小板药物正在进行临床试验。本文将对抗血小板药物的临床应用进展进行综述。

Clinical research progress of antiplatelet drugs

Acute coronary syndrome (ACS) is a common cardiovascular disease, which can lead to complications such as arrhythmia, heart failure and sudden death, which all seriously affect the quality of life of patients. Coronary atherosclerosis is the pathogenetic basis of ACS and platelets play a key role in the formation of atherosclerosis. Therefore, antiplatelet therapy is the cornerstone of the treatment of coronary heart disease. The commonly used clinical antiplatelet drugs mainly include thromboxane A2 inhibitors, P2Y12 receptor antagonists and glycoprotein Ⅱb/ⅡIa inhibitors, and a variety of new antiplatelet drugs are in clinical trials. This article will review the clinical application of antiplatelet drugs.